OpGen Inc (NASDAQ:OPGN) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 128,600 shares, a growth of 37.2% from the May 30th total of 93,700 shares. Based on an average trading volume of 483,600 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.6% of the shares of the company are short sold.
OPGN stock traded down $0.01 during midday trading on Friday, hitting $0.36. 58,944 shares of the stock traded hands, compared to its average volume of 398,906. The firm has a market capitalization of $6.35 million, a price-to-earnings ratio of -0.16 and a beta of 0.83. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.27 and a current ratio of 1.37. The company’s fifty day moving average is $0.42. OpGen has a 1-year low of $0.35 and a 1-year high of $2.41.
OpGen (NASDAQ:OPGN) last released its quarterly earnings results on Tuesday, May 14th. The medical research company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.08). The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $1.20 million. OpGen had a negative net margin of 454.23% and a negative return on equity of 313.92%. Sell-side analysts anticipate that OpGen will post -0.75 EPS for the current year.
An institutional investor recently bought a new position in OpGen stock. Bank of New York Mellon Corp purchased a new stake in shares of OpGen Inc (NASDAQ:OPGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,688 shares of the medical research company’s stock, valued at approximately $27,000. Bank of New York Mellon Corp owned 0.24% of OpGen as of its most recent filing with the Securities & Exchange Commission. 10.44% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $1.50 price objective on shares of OpGen in a research note on Sunday, May 19th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, Zacks Investment Research upgraded shares of HAYS PLC/ADR from a “sell” rating to a “hold” rating in a research report on Tuesday, June 18th.
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Read More: Blue-Chip Stocks
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.